Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 4 Ovarian Neoplasms 2 Colorectal Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Somatostatinoma 1 Small Cell Lung Carcinoma 1 Neoplasms 1 Metastatic Pancreatic Adenocarcinoma 1 Metastatic Adenocarcinoma of the Pancreas 1 Locally Advanced Pancreatic Carcinoma(LAPC) 1 Head and Neck Neoplasms 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Biliary Tract Neoplasms 1 Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 57 Paclitaxel 50 Cyclophosphamide 45 pembrolizumab 44 Carboplatin 41 Bevacizumab 38 Cisplatin 33 Docetaxel 31 Fluorouracil 30 Nivolumab 29 Capecitabine 29 Pemetrexed 24 Irinotecan 24 Oxaliplatin 23 Dexamethasone 23 Ipilimumab 22 Leucovorin 21 Radiotherapy 20 Sorafenib 19 Doxorubicin 19 Everolimus 18 Cetuximab 18 fludarabine 17 Albumin-Bound Paclitaxel 17 trametinib 15 Sunitinib 15 Rituximab 15 Erlotinib Hydrochloride 15 130-nm albumin-bound paclitaxel 15 Prednisone 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neoplasms × irinotecan sucrosofate × Clear all

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed

512 enrolled 19 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡